Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

Area of Science:

• Neuropathology
• Biomarker Discovery
• Analytical Chemistry

Background:

• Alzheimer's disease (AD) involves amyloid plaques, tau tangles, and neurodegeneration.
• Current AD biomarkers are often developed using immunoassays.
• Neuropathological changes precede symptomatic neuronal network disturbances.

Purpose of the Study:

• To review the application of targeted mass spectrometry (TMS) for validating AD biomarkers.
• To explore TMS's potential in characterizing tau and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage.
• To discuss the prospects of using TMS in clinical research and AD diagnosis.

Main Methods:

• Review of existing literature on targeted mass spectrometry (TMS) in Alzheimer's disease research.
• Discussion of TMS's capabilities in protein quantification and characterization.
• Comparative analysis of TMS versus immunoassays for biomarker validation.

Main Results:

• TMS can validate and further characterize biomarkers for key AD pathologies.
• TMS offers a complementary approach to immunoassays for AD biomarker analysis.
• The review discusses the advantages and disadvantages of TMS in the context of AD diagnostics.

Conclusions:

• Targeted mass spectrometry (TMS) is a valuable tool for validating and characterizing Alzheimer's disease biomarkers.
• TMS holds significant potential for advancing AD clinical research and diagnostic capabilities.
• Integrating TMS with existing methods like immunoassays can provide a more comprehensive understanding of AD pathology.